Cargando…

PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging

Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that binds to low-density lipoprotein receptors. Efferocytosis is the process by which phagocytes remove apoptotic cells. Both PCSK9 and efferocytosis play important roles in regulating redox biology and inflammation, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shijie, Wu, Jinzi, Stolarz, Amanda, Zhang, Huiliang, Boerma, Marjan, Byrum, Stephanie D., Rusch, Nancy J, Ding, Zufeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240829/ https://www.ncbi.nlm.nih.gov/pubmed/37284459 http://dx.doi.org/10.7150/thno.83914

Ejemplares similares

Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
por: Stolarz, Amanda J., et al.
Publicado: (2022)

NLRP3 inflammasome via IL-1β regulates PCSK9 secretion
por: Ding, Zufeng, et al.
Publicado: (2020)

NLRP3 inflammasome via IL-1β regulates PCSK9 secretion: Erratum
por: Ding, Zufeng, et al.
Publicado: (2022)

Defective efferocytosis of vascular cells in heart disease
por: Singh, Bandana, et al.
Publicado: (2022)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Leptin and PCSK9 concentrations are associated with vascular endothelial cytokines in patients with stable coronary heart disease
por: Wang, Qiang, et al.
Publicado: (2022)

Efferocytosis in multisystem diseases
por: Zhang, Yifan, et al.
Publicado: (2022)

Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis
por: Yurdagul, Arif, et al.
Publicado: (2018)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
por: Sun, Hua, et al.
Publicado: (2018)

Efferocytosis in the tumor microenvironment
por: Werfel, Thomas A., et al.
Publicado: (2018)

Efferocytosis and autoimmune disease
por: Kawano, Mahiru, et al.
Publicado: (2018)

Efferocytosis and Respiratory Disease
por: Zheng, Wenxue, et al.
Publicado: (2023)

PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system
por: Lee, Jounghyun H., et al.
Publicado: (2023)

PCSK9-Inhibition to Quench Vascular Injury in Chronic Limb Threatening Ischemia
por: Okazaki, Ross, et al.
Publicado: (2023)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Caspase-9 driven murine model of selective cell apoptosis and efferocytosis
por: Batoon, Lena, et al.
Publicado: (2023)

PCSK9 mediates the oxidative low-density lipoprotein-induced pyroptosis of vascular endothelial cells via the UQCRC1/ROS pathway
por: Zeng, Junfa, et al.
Publicado: (2021)

PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
por: Kong, Ni, et al.
Publicado: (2022)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Modulation of Macrophage Efferocytosis in Inflammation
por: Korns, Darlynn, et al.
Publicado: (2011)

The Role of Efferocytosis in Autoimmune Diseases
por: Abdolmaleki, Fereshte, et al.
Publicado: (2018)

Efferocytosis of Pathogen-Infected Cells
por: Karaji, Niloofar, et al.
Publicado: (2017)

Efferocytosis is impaired in Gaucher macrophages
por: Aflaki, Elma, et al.
Publicado: (2017)

Efferocytosis in the Central Nervous System
por: Zhao, Jiayi, et al.
Publicado: (2021)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

Insight into the Evolving Role of PCSK9
por: Maligłówka, Mateusz, et al.
Publicado: (2022)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
por: Grobelna, Malwina K., et al.
Publicado: (2019)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_albi9ae8p9ac5gqdubggrs57rk